Trial Profile
Randomized phase II trial of autologous vaccines consisting of adjuvant GM-CSF plus proliferating tumor cells versus GM-CSF plus dendritic cells loaded with proliferating tumor cells in patients with metastatic melanoma (MAC-VAC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Eltrapuldencel-T (Primary) ; Sargramostim
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms MAC-VAC
- 23 Apr 2020 According to an AiVita Biomedical media release, results from this study were published in the Journal of Translational Medicine.
- 04 Jun 2019 Results assessing survival for melanoma patients who were treated with patient specific vaccines by using data from two phase II studies presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2019 Pooled data from this and other trial (NCT00436930) were presented in an AiVita Biomedical Media Release.